<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Hyperthyroidism and goitre  v3.0 MeG-CLS-027</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="hyperthyroidism-and-goitre">Hyperthyroidism and goitre</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>Hyperthyroidism is excess production and/or secretion of thyroid hormones (overactive thyroid gland).</p>
<p>Goitre refers to enlargement of the thyroid gland. Maybe diffuse or nodular and may be associated with normal, decrease or increase thyroid hormone production.</p>
<p>Hyperthyroidism and goitre in The Gambia are most often caused either by Grave’s disease or by nodular disease. As everywhere, thyroid disease is more common in women than in men.</p>
<p>Nodular disease is probably linked to chronic iodine deficiency and is more common in older patients. It may or may not be associated with hyperthyroidism.</p>
<h2 id="target-user">Target User</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes.">Key areas of focus / New additions / Changes.</h2>
<p>This guideline addresses the diagnosis and management of hyperthyroidism and goitre.</p>
<h2 id="limitations">Limitations </h2>
<p>There is limited availability of an alternative to carbimazole in the country.</p>
<p>Limited access to surgeons skilled in thyroidectomy. There is no access to radioiodine treatment.</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>Goitre is a common presenting symptom of thyroid disease.</p>
<p>Other symptoms related to hyperthyroidism include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Unintentional weight loss (despite increased appetite) (although a few patients may gain weight, if excessive intake outstrips weight loss)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Shakiness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nervousness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Anxiety</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Increased perspiration</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Heat intolerance</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Palpitations</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Chest pain – often occurs in the absence of cardiovascular disease</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Frequent bowel movements</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Reduction in menstrual flow or oligomenorrhea</p>
</div></li>
</ul>
<p>Elderly patients may have only cardiovascular symptoms, commonly new onset atrial fibrillation.</p>
<p>Patients with Grave’s disease may also present with eye disease (proptosis, periorbital oedema, diplopia) and may have a past medical history of autoimmune disease (such as rheumatoid arthritis, vitiligo etc).</p>
<h2 id="examination-findings">Examination findings</h2>
<h3 id="general-examination">General examination</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Raised HR or AF</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypertension – with wide pulse pressure</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Warm moist, smooth skin,</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Lid lag, staring appearance</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Tremor</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Muscle weakness</p>
</div></li>
</ul>
<h3 id="thyroid">Thyroid</h3>
<p>In Grave’s disease, the thyroid is typically diffusely enlarged and firm. Multinodular goitres are softer, but may be much larger. Pain is very unusual.</p>
<h2 id="differential-diagnoses">Differential diagnoses</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Anxiety Disorders</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Panic Disorder</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Withdrawal Syndromes</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Delirium Tremens (DTs)</p>
</div></li>
</ul>
<h2 id="investigations">Investigations</h2>
<p>US of neck is essential to identify nodules.</p>
<p>ECG may show sinus tachycardia or atrial fibrillation (especially in elderly patients).</p>
<p>The most reliable screening measure of thyroid function is the thyroid-stimulating hormone (TSH) level. Hyperthyroidism is confirmed by the presence of a TSH level which is low or suppressed to unmeasurable levels (except in the case of secondary hyperthyroidism due to pituitary disease, which is not considered in this guideline).</p>
<p>If the TSH is low, then order free T<sub>3</sub> and free T<sub>4</sub> at the next appointment. The diagnosis is confirmed if these are raised. Sub-clinical hyperthyroidism is defined as a decreased but not undetectable TSH level (&lt; 0.5 mIU/L) in combination with serum concentrations of T<sub>3</sub> and T<sub>4</sub> that are within the reference range.</p>
<h2 id="management">Management </h2>
<h3 id="non-toxic-goitre">Non-toxic goitre</h3>
<p>This does not usually need any immediate treatment. Encourage the patient to use iodised salt. If the goitre is large or the patient is distressed, then consider referral to the surgeons at KGH or EFSTH.</p>
<h3 id="subclinical-hyperthyroidism">Subclinical hyperthyroidism</h3>
<p>Consider seeking specialist advice on managing subclinical hyperthyroidism in adults if they have:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>2 TSH readings lower than 0.1 mIU/L at least 3 months apart ]</p>
</div></li>
</ul>
<div data-custom-style="List Paragraph">
<p>AND</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>evidence of thyroid disease (for example, a goitre or positive thyroid antibodies) or symptoms of thyrotoxicosis.</p>
</div></li>
</ul>
<p>Consider seeking specialist advice on managing subclinical hyperthyroidism in all children and young people.</p>
<h3 id="hyperthyroidism.">Hyperthyroidism.</h3>
<p>Once hyperthyroidism is confirmed by a low TSH, it becomes necessary to check free T<sub>4</sub> and T<sub>3</sub> (fT<sub>3</sub>, fT<sub>4</sub>). .</p>
<p><span class="underline">Initial treatment</span></p>
<p>Before starting antithyroid drugs for adults, children and young people with hyperthyroidism, check <strong>full blood count</strong> and liver function tests.</p>
<p>Start</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>adults with HR &gt; 90 on Propranolol 40 mg TDS.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>children with HR &gt; 100 and cardiovascular symptoms on Propranolol 0.5-1.0 mg/kg TDS.</p>
</div></li>
</ul>
<p>Once the fT<sub>4</sub> is available, start Carbimazole as outlined in the table below.</p>
<table>
<thead>
<tr class="header">
<th><strong>fT<sub>4</sub></strong></th>
<th><strong>Adult dose</strong></th>
<th><strong>Children’s dose</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1.85 – 2.78 ng/dl</td>
<td>5-10 mg OD</td>
<td>0.25 mg/kg OD</td>
</tr>
<tr class="even">
<td>2.78 – 3.7 ng/dl</td>
<td>10-20 mg OD</td>
<td>0.5 mg/kg OD</td>
</tr>
<tr class="odd">
<td>3.7 – 5.55 ng/dl</td>
<td>30-40 mg OD</td>
<td>0.75 mg/kg OD</td>
</tr>
</tbody>
</table>
<p>Recheck fT<sub>3</sub> and fT<sub>4</sub> (but not TSH which is slow to normalize) 1 month after starting treatment. Once the levels of both are normal, reduce Carbimazole dose by 50% and then recheck again in 6/52.</p>
<p><span class="underline">Maintenance</span></p>
<p>Once the patient is euthyroid and stable on a maintenance dose of Carbimazole (typically 10 mg OD in adults), check the fT<sub>3</sub>, fT<sub>4</sub> every 3/12. Stop the propranolol.</p>
<p>Carbimazole is associated with a 1 in 1000 risk of agranulocytosis and a 3 in 10000 risk of liver failure.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Warn the patient to return urgently if they develop a febrile illness, pharyngitis, itchy rash, jaundice, change of colour of stool or urine, abdominal pain or bloating, anorexia, nausea or vomiting.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Check the FBC or LFTs as appropriate in any patient presenting with these symptoms.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If either have changed from baseline, then you may need to stop the carbimazole – remembering that there is no alternative treatment easily available in the Gambia.</p>
</div></li>
</ul>
<p><span class="underline">Further treatment</span></p>
<p>Patients with a toxic nodular goitre are very likely to need surgery once they are euthyroid and should be referred for this.</p>
<p>Patients with Grave’s disease who have been on treatment for 18 months or more may be able to stop treatment and remain in remission.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Review the patient clinically 1/12 after stopping treatment. If they are well, review 3 monthly and check TSH, fT<sub>3</sub>, fT<sub>4</sub> at each appointment until they have been euthyroid off treatment for 1 year. Then discharge the patient.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If they develop hyperthyroidism once again, then reestablish on treatment and, once they are euthyroid, refer for surgery.</p>
</div></li>
</ul>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<h2 id="refer-all-patients-with-possible-thyroid-disease-to-the-doctor.">Refer all patients with possible thyroid disease to the doctor. </h2>
<h2 id="references">References</h2>
<p>Erik D Schraga (30 May 2014). &quot;Hyperthyroidism, Thyroid Storm, and Graves Disease&quot;. Archived from the original on 5 April 2015. Retrieved 20 April 2015.</p>
<p>Hyperthyroidism&quot;. www.niddk.nih.gov. July 2012. Archived from the original on 4 April 2015. Retrieved 2 April 2015.</p>
<p>Ross et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid (2016) 26:1343-1421.</p>
<p>Thyroid disease: assessment and management NICE <span data-custom-style="prod-title">guideline [NG145]</span> <span data-custom-style="published-date">Published date: 20 November 2019.</span> <a href="https://www.nice.org.uk/guidance/NG145"><span data-custom-style="Hyperlink">https://www.nice.org.uk/guidance/NG145</span></a></p>
<p>Rose, DS 2019. Diagnosis of hyperthyroidism. UpToDate. Apr 17 2019.</p>
<p>Rose DS 2020. Overview of the clinical manifestations of hyperthyroidism in adults. UpToDate. Mar 23 2020.</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Chibuike Okpara</th>
<th>Date: 9 June 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Babatunde Awokola</td>
<td>Date: 2 July 2018</td>
</tr>
<tr class="even">
<td><strong>Reviewed by</strong></td>
<td>Name: Bubacarr Susso</td>
<td>Date: 01 November 2020</td>
</tr>
<tr class="odd">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="even">
<td>1.0</td>
<td>New document</td>
<td></td>
</tr>
<tr class="odd">
<td>2.0</td>
<td>Updated and transferred to new template</td>
<td>31 July 2020</td>
</tr>
<tr class="even">
<td>2.1</td>
<td>Executive summary added</td>
<td>31 July 2020</td>
</tr>
<tr class="odd">
<td>Review Comments (<em>if applicable)</em></td>
<td>Amendments to executive summary, introduction, limitations, examination findings, management of subclinical hyperthyroidism added, references updated</td>
<td>01 November 2022</td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
